2nd-generation HPV vaccine approved
Print Edition
A second-generation HPV vaccine has been approved by China Food and Drug Administration for clinical testing, the developer said yesterday.
It is the world鈥檚 second second-generation human papilloma virus (HPV) vaccine to reach the clinical test stage, following one developed by Merck, which also obtained permission for clinical testing in China.
The research is led by the National Institute of Diagnostics and Vaccine Development in Infectious Diseases, based at Xiamen University in southeast China鈥檚 Fujian Province.
The vaccine will be produced in Xiamen, if approved.
Compared with the first-generation vaccine, the new one can protect against five more high-risk types of HPV and two more low-risk types. It is estimated it will be able to prevent about 90 percent of cervical cancers and genital warts.
Developers at Xiamen University said the vaccine uses more cost-effective coliform bacteria as the effective antigen, while foreign companies use yeast or insect cells, giving it an edge in the market.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
